Greenwich Lifesciences Inc (GLSI) Stock Analysis

Greenwich Lifesciences Inc (GLSI) is a publicly traded company in the HEALTHCARE sector. It trades at $24.29, carries a market capitalization of $394.99M. This page summarizes the public market data, fundamentals, and frequently asked questions for GLSI, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $24.29
• Market Cap: $394.99M
• EPS: $-1.46
• 52-Week High: $34.10
• 52-Week Low: $7.78

Market Sentiment

Greenwich Lifesciences Inc currently has a Neutral sentiment score of 0.06.

About Greenwich Lifesciences Inc

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical firm based in Stafford, Texas, focused on developing innovative immunotherapies to combat cancer, particularly targeting HER2/neu-expressing tumors, including breast cancer. The company's lead product candidate, GP2, is designed to bolster the immune system's response against cancer cells, showcasing its potential to address significant unmet medical needs in oncology. With a promising pipeline and a strategic focus on transfo...

GNG Research Analysis

GNG Research scores Greenwich Lifesciences Inc (GLSI) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GLSI.

Frequently Asked Questions

Does GLSI pay dividends?

Greenwich Lifesciences Inc (GLSI) does not currently pay a regular dividend.

What is GLSI's market cap?

Greenwich Lifesciences Inc (GLSI) has a market capitalization of $394.99M with a current stock price of $24.29.